

Special Issue

Lung Cancer: Diagnosis and Targeted Therapies

Message from the Guest Editor

In the past decade, there have been incredible advances in the field of molecular oncology that have improved clinical management of lung cancer and outcome. Despite this, the drug therapy cure rate at the advanced stage for lung cancers remains low, necessitating the development of further innovative therapeutic strategies.

This Special Issue aims to publish original research papers and review articles related to advances in basic research on the genomics of lung cancer. Particular focus will be given to research using sequencing data expected to contribute to the development of novel cancer diagnostics and treatment techniques (including gene therapies) as well as new medical devices and drugs, such as studies on circulating tumor DNA, fusion gene, intratumor heterogeneity, tumor mutation burden, and microbiome. Furthermore, papers discussing cancer cell responses to molecular targeted therapies based on single-cell sequencing data will also be considered.

Guest Editor

Dr. Taichiro Goto

Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi 400-8506, Japan

Deadline for manuscript submissions

closed (20 February 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/127314

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/

[genes](https://genes.mdpi.com)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))